Humanwell Healthcare Group Co Ltd (Humanwell) is a pharmaceutical company. It provides generic drug formulations and over-the-counter (OTC) products for treating central nervous system (CNS), respiratory and dermatological diseases. Its product portfolio includes anesthetics (post-surgery), fertility regulation drugs; CNS medicines including sedative and sedation awaken drugs, anti-be chic and anti-epilepsy drugs; OTC drugs targeting digestive disorders, cold and flu, anti-inflammation, anti-infection and nutritional supplements; anti-infective drugs; and herbal medicines. The company offers its products in the dosage forms of injectables, capsules, oral liquids, syrup and granules. It operates in North America, Europe, Asia-Pacific and Africa. Humanwell is headquartered in Wuhan, Hubei, China.
Headquarters
China
Address
No. 666 Gaoxin Avenue, Donghu High-Tech District, Wuhan, Hubei, 430075
Website
www.humanwell.com.cn
Telephone
86 27 87597232
No of Employees
16,070
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
600079 (SHA)
Revenue (2021)
$3.3B
8.7%
(2021 vs 2020)
EPS
XYZ
Net Income (2021)
XYZ
88.6%
(2021 vs 2020)
Market Cap*
$4.5B
Net Profit Margin (2022)
XYZ
73.5%
(2021 vs 2020)
* As of and is in US$
Humanwell Healthcare Group Co Ltd premium industry data and analytics
Products and Services
| Products |
|---|
| Anesthetics |
| Fertility Regulation Drugs |
| Herbal Medicines |
| XYZ |
| XYZ |
| XYZ |
Competitor Comparison
| Key Parameters | Humanwell Healthcare Group Co Ltd | Shanghai Fosun Pharmaceutical (Group) Co Ltd | Huadong Medicine Co Ltd | Jinyao Pharmaceutical Co Ltd | Guilin Sanjin Pharmaceutical Co Ltd |
|---|---|---|---|---|---|
| Headquarters | China | China | China | China | China |
| City | Wuhan | Shanghai | Hangzhou | Tianjin | Guilin |
| State/Province | Hubei | Shanghai | Zhejiang | Tianjin | Guangxi |
| No. of Employees | 16,070 | 38,399 | 14,061 | 2,569 | 2,720 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Li Jie | Chairman | Executive Board | 2005 | 68 |
| Deng Xiafei | President; Director | Executive Board | 2020 | 60 |
| Wu Yajun | Chief Financial Officer; Vice President | Senior Management | 2005 | 53 |
| Li Qianlun | Secretary; Vice President | Senior Management | 2013 | 44 |
| Yu Qun | Vice President | Senior Management | 2020 | 51 |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward